Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer
Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.
Source: news-medical.net